FDG PET Parkinson'un hastalıkla ilgili paterni, erken evre hastalığındaki klinik denemeler için bir biyobelirteç olarak.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

BackgroundThe development of therapeutic interventions for Parkinson disease (PD) is challenged by disease complexity and subjectivity of symptom evaluation. A Parkinson's Disease Related Pattern (PDRP) of glucose metabolism via fluorodeoxyglucose positron emission tomography (FDG-PET) has been reported to correlate with motor symptom scores and may aid the detection of disease-modifying therapeutic effects.ObjectivesWe sought to independently evaluate the potential utility of the PDRP as a biomarker for clinical trials of early-stage PD.MethodsTwo machine learning approaches (Scaled Subprofile Model (SSM) and NPAIRS with Canonical Variates Analysis) were performed on FDG-PET scans from 17 healthy controls (HC) and 23 PD patients. The approaches were compared regarding discrimination of HC from PD and relationship to motor symptoms.ResultsBoth classifiers discriminated HC from PD (p 2 = 0.24, p 2 = 0.23, p 2 = 0.25, p 2 = 0.16, p ConclusionsTwo independent analyses performed in a cohort of mild PD patients replicated key features of the PDRP, confirming that FDG-PET and multivariate classification can provide an objective, sensitive biomarker of disease stage with the potential to detect treatment effects on PD progression.

İlgili konular